Creso Pharma Limited (COPHF) Research

Creso Pharma Limited is a global pharmaceutical company focused on the development, registration, and commercialization of advanced cannabis and hemp-based solutions. These therapeutic products and nutraceuticals are designed for both human and animal health applications, with market presence spanning Europe, the Middle East, North America, and the Asia Pacific region. Beyond innovative product creation, the company also manages the cultivation, processing, and distribution of cannabis products, extending its reach to the retail sector. Its diverse portfolio includes specialized offerings such as anibidiol, a complementary nutritional supplement for companion animals. For human wellness, they provide cannaQIX, a nutraceutical blend of hemp oil extract, vitamins, and zinc, formulated to alleviate stress and bolster psychological and neurological functions. The company also manufactures topical and dermatological products, including cannaDOL, a CBD-infused gel combining cooling and warming essential oils. Established in 2015, Creso Pharma Limited maintains its headquarters in Nedlands, Australia.

Open Creso Pharma Limited (COPHF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.